一项关于甲胺苯吖啶（NSC 249992）和新制癌菌素（NSC 157365）治疗非小细胞支气管癌的随机II期研究。东部肿瘤协作组研究。

A randomized phase II study of m-AMSA (NSC 249992) and neocarzinostatin (NSC 157365) in non-small cell bronchogenic carcinoma. An Eastern Cooperative Group Study.

作者信息

Ettinger D S, Day R, Ferraro J A, Ruckdeschel J C, Woll J E, Creech R H, Vogl S E

出版信息

Am J Clin Oncol. 1983 Apr;6(2):167-70. doi: 10.1097/00000421-198304000-00004.

DOI:10.1097/00000421-198304000-00004

Abstract

Eighty-nine patients with advanced non-small cell bronchogenic carcinoma were treated with either m-AMSA 120 mg/m2 intravenously every 3 weeks or neocarzinostatin 2.0 mg/m2 intravenously daily X 5 every 4 weeks. There were no responses in 40 evaluable patients who received m-AMSA and three partial responses (7.5%) in 40 patients who received neocarzinostatin. Two patients receiving m-AMSA had drug-related deaths. For m-AMSA the major toxicities were hematologic, while for neocarzinostatin the major toxicities were hematologic, gastrointestinal, and fever. We conclude that m-AMSA is inactive while neocarzinostatin has minimal activity in non-small cell bronchogenic carcinoma.

摘要

89例晚期非小细胞支气管源性癌患者接受了以下治疗：每3周静脉注射m-AMSA 120 mg/m²，或每4周静脉注射新制癌菌素2.0 mg/m²，每日1次，共5天。40例接受m-AMSA治疗的可评估患者均无反应，40例接受新制癌菌素治疗的患者中有3例部分缓解（7.5%）。2例接受m-AMSA治疗的患者死于药物相关原因。m-AMSA的主要毒性为血液学毒性，而新制癌菌素的主要毒性为血液学毒性、胃肠道毒性和发热。我们得出结论，m-AMSA在非小细胞支气管源性癌中无活性，而新制癌菌素的活性极小。